ReviewEcoSal Plus2024
The rise, fall, and resurgence of phage therapy for urinary tract infection.
Review in EcoSal Plus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- Cocktail of genetically diverse lytic phages reduces uropathogenic Escherichia coli colonization in mouse urinary tract.Scientific reports · 2026Article
- Exploration of the genomic diversity of third-generation cephalosporin-resistantMicrobial genomics · 2026Article
- A comprehensive review on herbal approaches for treatment of urinary tract infections: Scope and challenges.Journal of pharmaceutical analysis · 2026Review
- Phage therapy for Drug-Resistant infections: Mechanisms, Evidence, and emerging clinical strategies.Molecular biology reports · 2025Review
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects.Expert reviews in molecular medicine · 2025Review
- Article
- Precision bacteriophage therapy for multidrug-resistant recurrent urinary tract infections: From biological rationale to clinical translation in Taiwan.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the face of rising antimicrobial resistance, bacteriophage therapy, also known as phage therapy, is seeing a resurgence as a potential treatment for bacterial infections including urinary tract infection (UTI). Primarily caused by uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.